Time: 19:15 – 21:00
Location: Victoria Convention Centre – Saanich – Level 1
*Dinner will be served.

Chair:

Speaker:

Objectives:

By participating in this learning program, health care providers can expect to:

• Recognize early RCC disease stage symptoms and underlying risk factors associated with recurrence rates
• Assess recent adjuvant RCC clinical trial data and their impact on current clinical practice
• Identify key patient factors important for the consideration of adjuvant therapy in early stage RCC

Sponsor:

Note: If you can not attend in-person, this session will be broadcasted live. Please register: https://www.cua.org/event/29712

Approximate start time (following Part 1): 20:15 – 21:00
Location: Victoria Convention Centre – Saanich – Level 1
*Dinner will be served at 19:15.

Chair:

Speakers:

Objectives:

By participating in this learning program, health care providers can expect to:

• Discuss the importance of genetic testing for their patients with advanced prostate cancer.
• Understand the efficacy and safety data from randomized control trials investigating PARPi in mCRPC
• Apply the practical knowledge gained from real-world, case-based discussion surrounding PARPi use in
  patients with mCRPC

Sponsor:

Note: If you can not attend in-person, this session will be broadcasted live. Please register: https://www.cua.org/event/29712

Time: 07:45 – 08:50
Location: Victoria Convention Centre – Saanich – Level 1
*Hot Breakfast will be served.

Chair:

Speakers:

Objectives:

By participating in this learning program, health care providers can expect to:

• Overview of established mUC treatment landscape in Canada.
• Exploring the changing landscape of mUC treatment and patientfactors that could affect treatment choices.
• Discussing practical considerations for future treatment choices in mUC through patient case study.

Sponsor:

Time: 16:30 – 17:30
Location: Victoria Convention Centre – Saanich – Level 1
*Refreshments will be served.

Speakers:

Objectives:

By participating in this learning program, health care providers can expect to:

• Gain comprehensive clinical insights into in-clinic experience with Radioligand Therapy (RLT) for metastatic castration-resistant prostate cancer (mCRPC) in Canada.
• Collect valuable perspectives to enhance internal practices within multidisciplinary teams, aiming to optimize the patient journey for individuals with mCRPC.
• Review the latest clinical advancements and forthcoming clinical trials in RLT within the Canadian healthcare landscape.

Sponsor:

Time: 14:50 – 15:45
Location: Victoria Convention Centre – Plenary

Speakers:

Objectives:

By participating in this learning program, health care providers can expect to:

• Review the latest evidence and discuss the optimal management for patients presenting with a high-risk biochemical recurrence (BCR) following surgery and/or radiation for localized prostate cancer.​
• Discuss the challenges of incorporating androgen receptor pathway inhibitors (ARPI) and PSMA-PET imaging into the management of high-risk BCR.

Sponsor:

Time: 07:30 – 09:00
Location: Victoria Convention Centre – Plenary
*Hot Breakfast will be served.

Speakers:

Objectives:

By participating in this learning program, health care providers can expect to:

• Explore the current vs future state of AI in the advanced prostate cancer disease continuum.
• Understand how AI may support the diagnosis and timely treatment of nmCRPC.
• Review how AI may facilitate multi-disciplinary care of advanced prostate cancer patients.

Sponsor: